Related Experiment Video
Updated: Oct 23, 2025

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
Morphomolecular Characterization of Serum Nanovesicles From Microbiomes Differentiates Stable and Infarcted
Camila Rodrigues Moreno1, José Antonio Franchini Ramires2, Paulo Andrade Lotufo3
1Laboratorio de Patologia Cardiaca, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Abstract:
Microbial communities are considered decisive for maintaining a healthy situation or for determining diseases. Acute myocardial infarction (AMI) is an important complication of atherosclerosis caused by the rupture of atheroma plaques containing proinflammatory cytokines, reactive oxygen species, oxidized low-density lipoproteins (oxLDL), damaged proteins, lipids, and DNA, a microenvironment compatible with a pathogenic microbial community. Previously, we found that archaeal DNA-positive infectious microvesicles (iMVs) were detected in vulnerable plaques and in the sera of Chagas disease patients with heart failure. Now, we characterize and quantify the levels of serum microbiome extracellular vesicles through their size and content using morphomolecular techniques to differentiate clinical outcomes in coronary artery disease (CAD). We detected increased numbers of large iMVs (0.8-1.34 nm) with highly negative surface charge that were positive for archaeal DNA, Mycoplasma pneumoniae antigens and MMP9 in the sera of severe AMI patients, strongly favoring our hypothesis that pathogenic archaea may play a role in the worst outcomes of atherosclerosis. The highest numbers of EVs <100 nm (exosomes) and MVs from 100 to 200 nm in the stable atherosclerotic and control healthy groups compared with the AMI groups were indicative that these EVs are protective, entrapping and degrading infectious antigens and active MMP9 and protect against the development of plaque rupture. Conclusion: A microbiome with pathogenic archaea is associated with high numbers of serum iMVs in AMI with the worst prognosis. This pioneering work demonstrates that the morphomolecular characterization and quantification of iEVs in serum may constitute a promising serum prognostic biomarker in CAD.
Insights
Pathogenic archaea and infectious microvesicles (iMVs) in the blood are linked to severe acute myocardial infarction (AMI). Smaller extracellular vesicles (EVs) appear protective against atherosclerosis and plaque rupture.
Area of Science:
- Microbiology
- Cardiovascular Medicine
- Biotechnology
Background:
- Microbial communities influence health and disease, including atherosclerosis.
- Acute myocardial infarction (AMI) involves plaque rupture with a pro-inflammatory microenvironment.
- Previous work identified archaeal DNA-positive infectious microvesicles (iMVs) in heart failure patients.
Purpose of the Study:
- To characterize and quantify serum microbiome extracellular vesicles (EVs) to differentiate coronary artery disease (CAD) clinical outcomes.
- To investigate the role of archaea and iMVs in severe AMI.
- To explore the protective potential of smaller EVs.
Main Methods:
- Morphomolecular techniques were used to analyze the size and content of serum microbiome EVs.
- Quantification of iMVs, exosomes, and other microvesicles (MVs) was performed.
- Analysis focused on differentiating between severe AMI, stable atherosclerosis, and healthy control groups.
Main Results:
- Severe AMI patients showed increased numbers of large iMVs (0.8-1.34 nm) positive for archaeal DNA, *Mycoplasma pneumoniae* antigens, and MMP9.
- Stable atherosclerotic and healthy groups had higher numbers of smaller EVs (<100 nm, exosomes) and MVs (100-200 nm).
- These smaller EVs and MVs were associated with entrapping and degrading infectious antigens and MMP9, suggesting a protective role.
Conclusions:
- A microbiome with pathogenic archaea correlates with high serum iMV levels in AMI patients with poor prognosis.
- The morphomolecular characterization of serum iEVs shows promise as a prognostic biomarker for CAD.
- Smaller EVs may play a protective role against atherosclerosis progression and plaque rupture.

